News

ANX1502 tablet shows promise in proof-of-concept CAD trial

Annexon Biosciences’ new tablet formulation of its experimental therapy ANX1502 reduced key clinical and biomarker measures in the three cold agglutinin disease (CAD) patients so far enrolled in a proof-of-concept clinical trial. “In patients treated with the oral small molecule ANX1502, we are encouraged by the changes in…

Uncommon cellular process in blood may help make AIHA diagnosis

Nearly half of children and teens with autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold agglutinin disease (CAD)  — have signs of erythrophagocytosis, or the removal of old and damaged red blood cells by immune cells, in blood samples, a small study shows. While erythrophagocytosis…

CAD likely caused blood clot during brain surgery: Case report

Cold agglutinin disease (CAD) was the likely cause of blood clot formation during brain surgery in a 57-year-old man, despite measures to prevent his body temperature from getting too low, a case study in Turkey showed. Because the clot occurred at the site where two brain blood vessels were…

Rituximab treatment effective in combined CAD, autoimmune disease

A man with rheumatoid arthritis and cold agglutinin disease (CAD) achieved complete remission following treatment with rituximab, an antibody-based therapy commonly used off-label for CAD, a recent case study indicates. Rituximab therapy also treated the man’s cooccurring immune thrombocytopenia, an autoimmune disorder marked by the destruction of platelets, which…